CO7160077A2 - Compuestos de pirazol sustituidos como antagonistas de lpar - Google Patents

Compuestos de pirazol sustituidos como antagonistas de lpar

Info

Publication number
CO7160077A2
CO7160077A2 CO14279332A CO14279332A CO7160077A2 CO 7160077 A2 CO7160077 A2 CO 7160077A2 CO 14279332 A CO14279332 A CO 14279332A CO 14279332 A CO14279332 A CO 14279332A CO 7160077 A2 CO7160077 A2 CO 7160077A2
Authority
CO
Colombia
Prior art keywords
compounds substituted
pyrazole compounds
lpar antagonists
lpar
antagonists
Prior art date
Application number
CO14279332A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7160077(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO7160077A2 publication Critical patent/CO7160077A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO14279332A 2012-06-20 2014-12-19 Compuestos de pirazol sustituidos como antagonistas de lpar CO7160077A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20

Publications (1)

Publication Number Publication Date
CO7160077A2 true CO7160077A2 (es) 2015-01-15

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14279332A CO7160077A2 (es) 2012-06-20 2014-12-19 Compuestos de pirazol sustituidos como antagonistas de lpar

Country Status (22)

Country Link
US (1) US20150259295A1 (cg-RX-API-DMAC10.html)
EP (1) EP2864294A1 (cg-RX-API-DMAC10.html)
JP (1) JP2015520201A (cg-RX-API-DMAC10.html)
KR (1) KR20150011003A (cg-RX-API-DMAC10.html)
CN (1) CN104411690A (cg-RX-API-DMAC10.html)
AU (1) AU2013279510A1 (cg-RX-API-DMAC10.html)
BR (1) BR112014031108A2 (cg-RX-API-DMAC10.html)
CA (1) CA2869602A1 (cg-RX-API-DMAC10.html)
CL (1) CL2014003242A1 (cg-RX-API-DMAC10.html)
CO (1) CO7160077A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140516A (cg-RX-API-DMAC10.html)
EA (1) EA201492283A1 (cg-RX-API-DMAC10.html)
HK (1) HK1206341A1 (cg-RX-API-DMAC10.html)
IL (1) IL236091A0 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN09347A (cg-RX-API-DMAC10.html)
MA (1) MA37765A1 (cg-RX-API-DMAC10.html)
MX (1) MX2014014105A (cg-RX-API-DMAC10.html)
PE (1) PE20142445A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014502364A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201407229UA (cg-RX-API-DMAC10.html)
UA (1) UA109867C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013189862A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
KR102698386B1 (ko) * 2017-12-19 2024-08-22 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CA3158743A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
EP4337641A1 (en) * 2021-05-11 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US12503454B2 (en) 2021-05-13 2025-12-23 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR20240115978A (ko) 2021-12-08 2024-07-26 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698335A4 (en) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (en) * 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
JP2014508111A (ja) * 2010-12-07 2014-04-03 アミラ ファーマシューティカルス,インコーポレーテッド リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用
US8975235B2 (en) * 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors

Also Published As

Publication number Publication date
MX2014014105A (es) 2015-03-05
BR112014031108A2 (pt) 2017-06-27
SG11201407229UA (en) 2014-12-30
CN104411690A (zh) 2015-03-11
JP2015520201A (ja) 2015-07-16
PE20142445A1 (es) 2015-01-28
UA109867C2 (ru) 2015-10-12
IL236091A0 (en) 2015-02-01
CA2869602A1 (en) 2013-12-27
EA201492283A1 (ru) 2015-04-30
HK1206341A1 (en) 2016-01-08
MA37765A1 (fr) 2017-04-28
EP2864294A1 (en) 2015-04-29
WO2013189862A1 (en) 2013-12-27
IN2014DN09347A (cg-RX-API-DMAC10.html) 2015-07-17
PH12014502364A1 (en) 2015-01-12
US20150259295A1 (en) 2015-09-17
CR20140516A (es) 2014-12-01
KR20150011003A (ko) 2015-01-29
CL2014003242A1 (es) 2015-03-20
AU2013279510A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
CO7160077A2 (es) Compuestos de pirazol sustituidos como antagonistas de lpar
CL2019002103A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
CL2014001174A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades.
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
PE20170502A1 (es) ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
UY34959A (es) Dihidropiridona p1 como inhibidores del factor xia
MX2015008233A (es) Nuevos derivados de quinolona.
ECSP14013215A (es) Compuestos novedosos
DOP2015000069A (es) Piridinonas bicíclicas novedosas
ECSP16074478A (es) Compuestos novedosos
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
UY32755A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
BR112015003998A2 (pt) compostos de cianopirazol lpar-substituídos